Navigation Links
Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
Date:11/4/2013

LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of RG-101 will be presented in a late-breaking poster session at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in Washington, D.C. on Monday, November 4, 2013 from 8:00 a.m. Eastern Standard Time (EST) to 5:30 p.m. EST. The poster is available on the Company's website at http://www.regulusrx.com.        

"RG-101 utilizes a unique mechanism of action by targeting microRNA-122, a liver-specific host factor for stability, replication and translation of HCV.  We believe that therapies that target host-encoded factors essential for HCV replication may act as attractive combination agents because they may demonstrate activity across all HCV genotypes and may have a high barrier to resistance," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  "We continue to be encouraged by the preclinical data seen to date and believe that RG-101 has the potential to be a best-in-class host factor agent.  In the near term, we expect to file our application with regulatory authorities and look forward to commencing clinical trials in man in early 2014."

Late-Breaking Poster on RG-101 – Monday, November 4, 2013, 8:00 a.m. EST – 5:30 p.m. EST

-RG-101, a GalNAc-conjugated anti-miR Employing a Unique Mechanism of Action by Targeting Host Factor MicroRNA-122 (miR-122), Demonstrates Potent Activity and Reduction of HCV in Preclinical Studies- '/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
3. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
7. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
8. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
9. John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
10. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
11. Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... RNA viruses, today announced a research collaboration with ... testing of the Company,s lead compound, SB 9200, ... against which currently there are no effective antiviral ... proprietary Small Molecule Nucleic Acid Hybrid (SMNH) ...
(Date:9/18/2014)... ROCKVILLE, Md. , Sept. 18, 2014 ... a biotechnology company with fully integrated commercial and drug ... oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary focus on China , announce ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
(Date:9/19/2014)... September 19, 2014 Yisrayl Hawkins, Pastor of ... expounding on the need to protect children. He begins by ... Michael Brown and reminds that there are many other children, ... says violence is spreading faster than cancer all over the ... “There are close to seven billion Michaels in the world ...
(Date:9/19/2014)... Los Angeles, California (PRWEB) September 19, 2014 ... a younger man for companionship and intimacy, and there are ... connection with an experienced, mature woman. SeekingCougar.com now ... , This online dating website caters to older women, and ... offers an easy and convenient way for these people to ...
(Date:9/19/2014)... VogueQueen.com has recently unveiled a ... ladies more beautiful at their weddings. The new range ... The company’s new products are made for the coming ... for all the global clients. , “The ... have ordered several items on its website. I'm very ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 Reduce bags ... ingredients made just for these issues in a serum. ... Haloxyl and Eyeliss," says Kathy Heshelow, founder of Sublime ... circulation and boosting collagen, to improve the eye area." ... serum for wrinkles, dark circles and bags at ...
(Date:9/18/2014)... 18, 2014 Defendants in more ... currently pending in Pennsylvania’s Philadelphia Court of Common ... on behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard ... 11th, the defendants maintain that circumstances surrounding the ... lawsuits have no connection to Pennsylvania. The filings ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3
... study authored by a UT Southwestern Medical Center researcher has ... than a placebo in several other applications previously thought to ... of drugs used to increase red blood cells in patients ... in a study of 4,038 patients, it did little to ...
... ... therapy partner enlisting the public to send free treatment e-cards to the military and ... ... for a Healthier Life, today launched an online holiday program advancing the company,s commitment ...
... helps ID early breast cancer, 42 percent in study declined free ... high risk of breast cancer, an MRI can help detect malignancies ... 42 percent of such women in a new study said no ... wanted to have MRI, even though it was no cost to ...
... , ... saw exciting research progress, unprecedented opportunities on the horizon, and more ... economic and financial challenges, the National Multiple Sclerosis Society continues to ... provided over $33.5 million to support 345 new and ongoing projects ...
... MOINES, Iowa, Dec. 22 Palisade Systems, the leader in ... has completed internal certification of its PacketSure 7.6 service to ... services and software. , More and more companies are becoming ... recent article in eMarketer, close to 70 percent of small ...
... ... a comprehensive New Jersey anti-poverty charity, seeks year-end charitable contributions to meet an increasing need. ... Paterson, NJ (PRWEB) December ... Jersey during the current economic recession. By giving a charitable contribution to this trustworthy ...
Cached Medicine News:Health News:Anemia drug not helpful for kidney disease patients 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 3Health News:Many High-Risk Women Refuse Breast MRI 2Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 2Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 3Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 4Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 5Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 6Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 7Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 8Health News:Palisade PacketSure Certified for Twitter and Facebook 2Health News:Eva's Village, a Paterson, New Jersey Anti-Poverty Charity, Seeks End of Year Charitable Contributions to Help Poor in a Troubled Economy 2Health News:Eva's Village, a Paterson, New Jersey Anti-Poverty Charity, Seeks End of Year Charitable Contributions to Help Poor in a Troubled Economy 3
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: